The stock of ImmuCell Corporation (NASDAQ:ICCC) hit a new 52-week low and has $4.87 target or 12.00% below today’s $5.53 share price. The 8 months bearish chart indicates high risk for the $22.97M company. The 1-year low was reported on Nov, 1 by Barchart.com. If the $4.87 price target is reached, the company will be worth $2.76M less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock. About 27,249 shares traded hands or 86.48% up from the average. ImmuCell Corporation (NASDAQ:ICCC) has declined 19.57% since March 30, 2016 and is downtrending. It has underperformed by 22.58% the S&P500.
Analysts await ImmuCell Corporation (NASDAQ:ICCC) to report earnings on November, 10.
According to Zacks Investment Research, “ImmuCell Corp. is a biotechnology company striving to build shareholder value by commercializing proprietary technologies and helping dairy and beef producers and their veterinarians manage disease and reproduction in their herds. The company is also conducting an open label, efficacy study of DiffGAM, a human application of its milk-derived passive antibody technology for use as an alternative to antibiotics in the treatment and/or prevention of Clostridium difficile-associated diarrhea.”
Insitutional Activity: The institutional sentiment decreased to 1.5 in Q2 2016. Its down 12.50, from 14 in 2016Q1. The ratio worsened, as 0 funds sold all ImmuCell Corporation shares owned while 4 reduced positions. 0 funds bought stakes while 6 increased positions. They now own 911,107 shares or 50.10% less from 1.83 million shares in 2016Q1.
Healthinvest Partners last reported 168,323 shares in the company. Minerva Advsr owns 14,559 shares or 0.07% of their US portfolio. The New York-based Morgan Stanley has invested 0% in ImmuCell Corporation (NASDAQ:ICCC). Northpointe Capital Ltd, a Michigan-based fund reported 253,502 shares. Essex Financial Svcs Inc holds 0.04% or 23,776 shares in its portfolio. Acadian Asset Mgmt Ltd Liability holds 0% or 1,923 shares in its portfolio. Heartland Advsrs has 0.08% invested in the company for 204,972 shares. Tower Cap Ltd Liability Company (Trc) holds 0% of its portfolio in ImmuCell Corporation (NASDAQ:ICCC) for 330 shares. Creative Planning has invested 0% of its portfolio in ImmuCell Corporation (NASDAQ:ICCC). Walleye Trading Ltd has invested 0% of its portfolio in ImmuCell Corporation (NASDAQ:ICCC). Moreover, Royal Bank Of Canada has 0% invested in ImmuCell Corporation (NASDAQ:ICCC) for 1,000 shares. Wells Fargo And Communications Mn last reported 0% of its portfolio in the stock. Natl Bank Of America Corporation De has 0% invested in the company for 2,032 shares. Blackrock Fund Advsrs has 0% invested in the company for 679 shares. The Pennsylvania-based Vanguard has invested 0% in ImmuCell Corporation (NASDAQ:ICCC).
Insider Transactions: Since July 7, 2016, the stock had 1 buy, and 2 insider sales for $8,949 net activity. Shares for $21,431 were bought by Cunningham David on Monday, August 22. CRABB JOSEPH H sold $17,711 worth of stock or 2,691 shares.
More notable recent ImmuCell Corporation (NASDAQ:ICCC) news were published by: Quotes.Wsj.com which released: “Immucell Corp. ICCC (US: Nasdaq)” on February 11, 2011, also Streetinsider.com with their article: “Immucell Corp (ICCC) Offers Prelim. Q3 Results; Says Sales Fell 20%” published on October 18, 2016, Marketwired.com published: “ImmuCell Corporation Announces Closing of $3.5 Million Private Placement of …” on October 21, 2016. More interesting news about ImmuCell Corporation (NASDAQ:ICCC) were released by: Benzinga.com and their article: “10 Biggest Mid-Day Losers For Tuesday” published on October 18, 2016 as well as Marketwired.com‘s news article titled: “ImmuCell to Announce Second Quarter 2016 Financial Results” with publication date: August 03, 2016.
ICCC Company Profile
ImmuCell Corporation, incorporated on February 9, 1987, is an animal health company. The Firm operates in the development, acquisition, manufacture and sale of products that improve the health and productivity of cows for the dairy and beef industries segment. The Firm has developed products that provide immediate immunity to newborn dairy and beef cattle, and is developing product line extensions of its existing products that address mastitis. The Company’s lead product, First Defense, is manufactured from cows’ colostrum (the milk that a cow produces immediately after giving birth) utilizing its vaccine and milk protein purification technologies. The Company’s Wipe Out Dairy Wipes are made from a non-woven fabric that allows for a vigorous cleaning. The Firm also developed California Mastitis Test (CMT), which is used for bulk tank, as well as individual cow sample monitoring and is used to determine which quarter of the udder is mastitic. The Company’s product development initiative is Mast Out, a Nisin intramammary treatment of subclinical mastitis in lactating dairy cows.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.